Explore the vast range of titles available.

Microbeam radiation therapy (MRT) is a radiotherapy technique combining spatial fractionation of the dose distribution on a micrometric scale, X-rays in the 50–500 keV range and dose rates up to 16 × 10 3  Gy s −1 . Nowadays, in vivo dosimetry remains a challenge due to the ultra-high radiation fluxes involved and the need for high-spatial-resolution detectors. The aim here was to develop a striped diamond portal detector enabling online microbeam monitoring during synchrotron MRT treatments. The detector, a 550 µm bulk monocrystalline diamond, is an eight-strip device, of height 3 mm, width 178 µm and with 60 µm spaced strips, surrounded by a guard ring. An eight-channel ASIC circuit for charge integration and digitization has been designed and tested. Characterization tests were performed at the ID17 biomedical beamline of the European Synchrotron Radiation Facility (ESRF). The detector measured direct and attenuated microbeams as well as interbeam fluxes with a precision level of 1%. Tests on phantoms (RW3 and anthropomorphic head phantoms) were performed and compared with simulations. Synchrotron radiation measurements were performed on an RW3 phantom for strips facing a microbeam and for strips facing an interbeam area. A 2% difference between experiments and simulations was found. In more complex geometries, a preliminary study showed that the absolute differences between simulated and recorded transmitted beams were within 2%. Obtained results showed the feasibility of performing MRT portal monitoring using a microstriped diamond detector. Online dosimetric measurements are currently ongoing during clinical veterinary trials at ESRF, and the next 153-strip detector prototype, covering the entire irradiation field, is being finalized at our institution.

Practical applications of heat transport control with artificial metamaterials will heavily depend on the realization of thermal diodes/rectifiers, in which thermal conductivity depends on the heat flux direction. Whereas various macroscale implementations have been made experimentally, nanoscales realizations remain challenging and efficient rectification still requires a better fundamental understanding of heat carriers’ transport and nonlinear mechanisms. Here, we propose an experimental realization of a thermal rectifier based on two leads with asymmetric mass gradients separated by a ballistic spacer, as proposed in a recent numerical investigation, and measure its thermal properties electrically with the microbridge technique. We use a Si 3 N 4 nanobeam on which an asymmetric mass gradient has been engineered and demonstrate that in its current form, this structure does not allow for thermal rectification. We explain this by a combination of too weak asymmetry and non-linearities. Our experimental observations provide important information towards fabricating rigorous thermal rectifiers in the ballistic phonon transport regime, which are expected to open new possibilities for applications in thermal management and quantum thermal devices.

In the context of online ion range verification in particle therapy, the CLaRyS collaboration is developing Prompt-Gamma (PG) detection systems. The originality in the CLaRyS approach is to use a beam-tagging hodoscope in coincidence with the gamma detectors to provide both temporal and spatial information of the incoming ions. The ion range sensitivity of such PG detection systems could be improved by detecting single ions with a 100 ps (\\(\\sigma\\)) time resolution, through a quality assurance procedure at low beam intensity at the beginning of the treatment session. This work presents the investigations led to assess the performance of Chemical Vapor Deposition (CVD) diamond detectors to fulfill these requirements. A \\(^{90}\\)Sr beta source, 68 MeV protons, 95 MeV/u carbon ions and a synchrotron X-ray pulsed beam were used to measure the time resolution, single ion detection efficiency and proton counting capability of various CVD diamond samples. An offline technique, based on double-sided readout with fast current preamplifiers and used to improve the signal-to-noise ratio, is also presented. The different tests highlighted Time-Of-Flight resolutions ranging from 13 ps (\\(\\sigma\\)) to 250 ps (\\(\\sigma\\)), depending on the experimental conditions. The single 68 MeV proton detection efficiency of various large area polycrystalline (pCVD) samples was measured to be \\(>\\)96% using coincidence measurements with a single-crystal reference detector. Single-crystal CVD (sCVD) diamond proved to be able to count a discrete number of simultaneous protons while it was not achievable with a polycrystalline sample. Considering the results of the present study, two diamond hodoscope demonstrators are under development: one based on sCVD, and one of larger size based on pCVD. They will be used for the purpose of single ion as well as ion bunches detection, either at reduced or clinical beam intensities.

The optical transmission and reflection in between two metalized optical fiber tips is studied in the optical near-field and far-field domains. Besides aluminum-coated tips for near-field scanning optical microscopy (NSOM), specifically developed gold-coated fiber tips cut by focused ion beam (FIB) are investigated. Transverse transmission maps of sub-wavelength width clearly evidence optical near-field coupling between the tips for short tip distances and becomes essentially Gaussian-shaped for larger distances in the far-field regime. Moreover concentric reflection fringes observed for NSOM-type tips illustrate the influence of the receiving fiber tip on the emission pattern of the source tip.

For future quantum technologies the combination of a long quantum state lifetime and an efficient interface with external optical excitation are required. In solids, the former is for example achieved by individual spins, while the latter is found in semiconducting artificial atoms combined with modern photonic structures. One possible combination of the two aspects is reached by doping a single quantum dot, providing a strong excitonic dipole, with a magnetic ion, that incorporates a characteristic spin texture. Here, we perform four-wave mixing spectroscopy to study the system's quantum coherence properties. We characterize the optical properties of the undoped CdTe quantum dot and find a strong photon echo formation which demonstrates a significant inhomogeneous spectral broadening. Incorporating the Mn\\(^{2+}\\) ion introduces its spin-5/2 texture to the optical spectra via the exchange interaction, manifesting as six individual spectral lines in the coherent response. The random flips of the Mn-spin result in a special type of spectral wandering between the six transition energies, which is fundamentally different from the quasi-continuous spectral wandering that results in the Gaussian inhomogeneous broadening. Here, the discrete spin-ensemble manifests in additional dephasing and oscillation dynamics.

In recent years, interest in expanding from 2D to 3D systems has grown in the magnetism community, from exploring new geometries to broadening the knowledge on the magnetic textures present in thick samples, and with this arise the need for new characterization techniques, in particular tomographic imaging. Here, we present a new tomographic technique based on Fourier transform holography, a lensless imaging technique that uses a known reference in the sample to retrieve the object of interest from its diffraction pattern in one single step of calculation, overcoming the phase problem inherent to reciprocal-space-based techniques. Moreover, by exploiting the phase contrast instead of the absorption contrast, thicker samples can be investigated. We obtain a 3D full-vectorial image of a 800 nm-thick extended Fe/Gd multilayer in a 5\\(\\mu\\)m-diameter circular field of view with a resolution of approximately 80 nm. The 3D image reveals worm-like domains with magnetization pointing mostly out of plane near the surface of the sample but that falls in-plane near the substrate. Since the FTH setup is fairly simple, it allows modifying the sample environment. Therefore, this technique could enable in particular a 3D view of the magnetic configuration's response to an external magnetic field.

A whole series of complementary studies have been performed on the same, single nanowire containing a quantum dot: cathodoluminescence spectroscopy and imaging, micro-photoluminescence spectroscopy under magnetic field and as a function of temperature, and energy-dispersive X-ray spectrometry and imaging. The ZnTe nanowire was deposited on a Si 3 N 4 membrane with Ti/Al patterns. The complete set of data shows that the CdTe quantum dot features the heavy-hole state as a ground state, although the compressive mismatch strain promotes a light-hole ground state as soon as the aspect ratio is larger than unity (elongated dot). A numerical calculation of the whole structure shows that the transition from the heavy-hole to the light-hole configuration is pushed toward values of the aspect ratio much larger than unity by the presence of a (Zn,Mg)Te shell, and that the effect is further enhanced by a small valence band offset between the semiconductors in the dot and around it.

Background Ultrasonography (US) and dual-energy computed tomography (DECT) can assess urate burden in gout. The objective of this study was to compare the quantification of urate deposition provided by US to the one provided by DECT. Methods Patients with a diagnosis of gout were prospectively recruited to undergo quantification of urate deposition using US and DECT. US examination for tophi and the double contour (DC) sign was performed on the knees and feet and corresponding DECT scans provided volumes of tophi and of overall urate deposition. The primary endpoint was the intra-class correlation coefficient (ICC) of the volume of the index tophus measured by US and DECT and its 95% confidence interval (CI 95%). Results Of the 64 patients included, 34 presented with at least one tophus on US. DECT inter-reader agreement for urate deposition was perfect with an ICC of 1 (1–1) and good for the measurement of the index tophus with an ICC of 0.69 (0.47–0.83). The ICC for the measurement of the index tophus between the two techniques was poor with a value of 0.45 (0.1–0.71). The average ratio between the index tophi volume as assessed by DECT and US was 0.65. The number of DC-positive joints did not correlate with DECT volume of overall deposits (Spearman correlation coefficient of 0.23). Conclusions DECT measurements of tophi give smaller volumes to the same tophi measured with US, and US signs of urate deposition in joints do not correlate with overall DECT volumes of extra-articular deposition.

In advanced oestrogen receptor-positive, HER2-negative breast cancer, acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones, which might be sensitive to fulvestrant. The PADA-1 trial aimed to show the efficacy of an early change in therapy on the basis of a rising ESR1 mutation in blood (bESR1mut), while assessing the global safety of combination fulvestrant and palbociclib. We did a randomised, open-label, phase 3 trial in 83 hospitals in France. Women aged at least 18 years with oestrogen receptor-positive, HER2-negative advanced breast cancer and an Eastern Cooperative Oncology Group performance status of 0–2 were recruited and monitored for rising bESR1mut during first-line aromatase inhibitor (2·5 mg letrozole, 1 mg anastrozole, or 25 mg exemestane, orally once per day, taken continuously) and palbociclib (125 mg orally once per day on days 1–21 of a 28-day cycle) therapy. Patients with newly present or increased bESR1mut in circulating tumour DNA and no synchronous disease progression were randomly assigned (1:1) to continue with the same therapy or to switch to fulvestrant (500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1) and palbociclib (dosing unchanged). The randomisation sequence was generated within an interactive web response system using a minimisation method (with an 80% random factor); patients were stratified according to visceral involvement (present or absent) and the time from inclusion to bESR1mut detection (<12 months or ≥12 months). The co-primary endpoints were investigator-assessed progression-free survival from random assignment, analysed in the intention-to-treat population (ie, all randomly assigned patients), and grade 3 or worse haematological adverse events in all patients. The trial is registered with Clinicaltrials.gov (NCT03079011), and is now complete. From March 22, 2017, to Jan 31, 2019, 1017 patients were included, of whom 279 (27%) developed a rising bESR1mut and 172 (17%) were randomly assigned to treatment: 88 to switching to fulvestrant and palbociclib and 84 patients to continuing aromatase inhibitor and palbociclib. At database lock on July 31, 2021, randomly assigned patients had a median follow-up of 35·3 months (IQR 29·2–41·4) from inclusion and 26·0 months (13·8–34·3) from random assignment. Median progression-free survival from random assignment was 11·9 months (95% CI 9·1–13·6) in the fulvestrant and palbociclib group versus 5·7 months (3·9–7·5) in the aromatase inhibitor and palbociclib group (stratified HR 0·61, 0·43–0·86; p=0·0040). The most frequent grade 3 or worse haematological adverse events were neutropenia (715 [70·3%] of 1017 patients), lymphopenia (66 [6·5%]), and thrombocytopenia (20 [2·0%]). The most common grade 3 or worse adverse events in step 2 were neutropenia (35 [41·7%] of 84 patients in the aromatase inhibitor and palbociclib group vs 39 [44·3%] of 88 patients in the fulvestrant and palbociclib group) and lymphopenia (three [3·6%] vs four [4·5%]). 31 (3·1%) patients had grade 3 or worse serious adverse events related to treatment in the overall population. Three (1·7%) of 172 patients randomly assigned had one serious adverse event in step 2: one (1·2%) grade 4 neutropenia and one (1·2%) grade 3 fatigue among 84 patients in the aromatase inhibitor and palbociclib group, and one (1·1%) grade 4 neutropenia among 88 patients in the fulvestrant and palbociclib group. One death by pulmonary embolism in step 1 was declared as being treatment related. PADA-1 is the first prospective randomised trial showing that the early therapeutic targeting of bESR1mut results in significant clinical benefit. Additionally, the original design explored in PADA-1 might help with tackling acquired resistance with new drugs in future trials. Pfizer.